Acumen Pharmaceuticals Inc (ABOS)
$2.92
$-0.11
(-3.63%)
As on 28-Aug-2026 16:00EDT
Market cap
$211 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
3.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.6
-
Debt to Equity
0
-
Book Value
$0.8
-
EPS
$-1.6
-
Face value
--
-
Shares outstanding
72,317,285
5 Years Aggregate
CFO
$-110.45 Mln
EBITDA
$-60.60 Mln
Net Profit
$-289.71 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Acumen Pharmaceuticals Inc (ABOS)
| 38.4 | 32.7 | 15.0 | 110.1 | -22.6 | -31.0 | -- |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Acumen Pharmaceuticals Inc (ABOS)
| 22.7 | -54.9 | -28.9 | -20.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Acumen Pharmaceuticals Inc (ABOS)
|
2.9 | 211.2 | 0.0 | -105.0 | -- | -164.5 | -- | 3.8 |
| 84.9 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 72.1 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.5 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 105.4 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 351.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 533.8 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 600.7 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 344.8 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 144.3 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Acumen Pharmaceuticals Inc (ABOS)
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its... Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts. Read more
-
CEO & Director
Mr. Daniel J. O'Connell M.B.A.
-
CEO & Director
Mr. Daniel J. O'Connell M.B.A.
-
Headquarters
Newton, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Acumen Pharmaceuticals Inc (ABOS)
What is the current share price of Acumen Pharmaceuticals Inc (ABOS) Today?
The share price of Acumen Pharmaceuticals Inc (ABOS) is $2.92 (NASDAQ) as of 28-Aug-2026 16:00 EDT. Acumen Pharmaceuticals Inc (ABOS) has given a return of -22.61% in the last 3 years.
What is the current PB & PE ratio of Acumen Pharmaceuticals Inc (ABOS)?
Since, TTM earnings of Acumen Pharmaceuticals Inc (ABOS) is negative, P/E ratio is not available.
The P/B ratio of Acumen Pharmaceuticals Inc (ABOS) is 3.83 times as on 28-Aug-2026, a 28 discount to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-1.05 |
1.81 |
2024 |
-1.01 |
0.57 |
2023 |
-4.25 |
0.83 |
2022 |
-5.15 |
1.17 |
2021 |
-2.57 |
1.15 |
What is the 52 Week High and Low of Acumen Pharmaceuticals Inc (ABOS)?
The 52-week high and low of Acumen Pharmaceuticals Inc (ABOS) are Rs 3.60 and Rs 1.21 as of 30-Aug-2026.
What is the market cap of Acumen Pharmaceuticals Inc (ABOS)?
Acumen Pharmaceuticals Inc (ABOS) has a market capitalisation of $ 211 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Acumen Pharmaceuticals Inc (ABOS)?
Before investing in Acumen Pharmaceuticals Inc (ABOS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.